Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 701-215-9 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
The available information suggests that only minor amounts of sodium DTPMP are absorbed after ingestion (limited by physicochemical interactions within the gut) or skin contact (limited by hydrophilic nature). There are also not expected to be any major differences between animals and humans for these parameters.
Key value for chemical safety assessment
- Absorption rate - oral (%):
- 2
Additional information
Based on the available data for phosphonic acids (DTPMP, HEDP and ATMP), no major differences are expected to exist between animals and humans with regard to the absorption, distribution and elimination of phosphonic acid compounds in vivo. Also, based on physicochemical properties, the toxicokinetics of the salts of DTPMP are not expected to be different to those of the parent acid. Therefore the following information and predictions are applicable to the acid and salts.
Absorption
Oral
The physicochemical properties of DTPMP compounds, notably their high polarity, charge and complexing power, suggests that they will not be readily absorbed from the gastrointestinal tract. This is supported by experimental data on DTPMP-H which confirm that absorption after oral exposure is low, averaging 2-7% in animals. In a rat study by Procter and Gamble (1978) approximately 2% of a dose of DTPMP-H was absorbed from a gavage dose, and 98% of the dose was excreted in faeces within 72 hours of dosing.
Gastrointestinal pH is a major determinant influencing uptake following oral exposure of phosphonates. It is extremely acidic in the stomach (range: pH 1-4) and alkaline in the small intestine (pH 4-7). The number of ionisations of the phosphonic acid moiety increases with increasing pH, rising from 1 - 2 at low pH (i.e. stomach) to 4 - 6 at more neutral pH (reflective of conditions in the small intestine). The negative charge on each molecule also increases with each ionisation, further reducing the already low potential for uptake. Stability constants for the interaction of phosphonic acids with divalent metal ions are high, and indicate strong binding, especially at lower pHs.
Complexation of a metal with a phosphonic acid would produce an ion pair of charge close to neutral which might favour absorption; however the overall polarity of the complex would remain high thereby counteracting this potential. Overall, these considerations indicate that ingested phosphonic acid compounds will be retained within the gut lumen.
Dermal
Based on the very low log Kow value (-3.4) DTPMP would be too hydrophilic to cross the stratum corneum. Dermal absorption is therefore likely to be very low. In a dermal absorption study in rats with DTPMP-H (Procter and Gamble, 1978, Reliability 2), 89% of the applied radioactivity (0.6 mg/kg bw) was recovered from the test site 72 hours after application to rat skin, with negligible amounts in faeces (< 0.01%) and minor amounts in urine (< 2% ) and carcass (<1.5%).
Inhalation
The vapour pressure of DTPMP is extremely low (<10E-08 Pa). Consequently, inhalation of DTPMP (5-7 Na) vapour is not possible. It is possible that aerosol (from aqueous solution) of DTPMP could be inhaled. In addition, the very high water solubility of this substance suggests that absorption will be low. Any inhaled material would be expected to partition readily to mucus in the lungs, and hence be expectorated or ingested.
Distribution
In oral and dermal studies conducted by Procter and Gamble (1978) the concentrations of DTPMP in all tissues was extremely low, due to the low overall absorption (Table 1). In the oral study it was shown that most test substance was distributed to the bone, and this tissue had nine times more DTPMP than any other organ or tissue.
Bone imaging following 2 and 4 hour intravenous administration of radiolabelled DTPMP-H in rabbits (Subramanian et al., 1975) and rats (Goeckeler et al., 1978) confirms that DTPMP is preferentially distributed to bone, but that concentrations in the bone marrow are low in comparison with the bone and comparable with other tissues such as muscle, kidney and liver (Table 5.1.2).
Table 5.1.2 Distribution of DTPMP in tissues
Tissue | Distribution following oral administration (μg/kg) Procter and Gamble (1978) (species: rat) | Distribution following 2h intravenous administration (% dose/g) (2h) Goeckeler (1987) (species: rat) | Distribution following 4h intravenous administration (% dose/1% body weight) Subramanian (1975) (species: rabbit) | Distribution following 4h intravenous administration (% dose/1% body weight) Subramanian (1975) (species: rabbit) |
Radiolabel | carbon | 153-Sm | 85-Sr | 113m-In |
Blood | 0.05 ± 0.05 | 74 | 0.7 | 0.4 |
Plasma | 0.03 ± 0.02 | Not determined | Not determined | Not determined |
Average bone | 2.9 ± 0.79 | 30 | 8.1 | 4.8 |
Marrow | Below limit of detection | Not determined | 0.3 | 0.2 |
Muscle | Below limit of detection | 0.9 | 0.2 | 0.04 |
Kidney | 0.17 ± 0.03 | 0.4 | 0.9 | 2.3 |
Liver | 0.11 ± 0.02 | 0.3 | 0.3 | 0.2 |
Testes | 0.05 ± 0.007 | Not determined | Not determined | Not determined |
Metabolism
There are no data on the metabolism of DTPMP.
Excretion
Information is available on the elimination of 14C-DTPMP (neutralised sodium salt) following oral or dermal administration to SD rats. In an oral toxicokinetics study using SD rats and with 14C-DTPMP-H (neutralised to pH 7 with sodium hydroxide), 98% of a gavage dose (10 mg/kg bw, 7 μCi/kg bw), was excreted in the faeces within 72 hours (Procter and Gamble, 1978). Of the remaining dose 1.3% was found in urine (the majority within 24 hours) and 0.4% in expired CO2. Faecal elimination of unabsorbed material predominates after ingestion (up to 90% of dose). Following dermal application, the majority of the absorbed dose was excreted in urine within 24 hours of the start of exposure.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.